Afficher la couverture 'A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants | Pishesha, Novalia' en grand format
/5

0 avis

A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants

Archive ouverte

Pishesha, Novalia | Harmand, Thibault | Rothlauf, Paul | Praest, Patrique | Alexander, Ryan | van den Doel, Renate | Liebeskind, Mariel | Vakaki, Maria | Mccaul, Nicholas | Wijne, Charlotte | Verhaar, Elisha | Pinney, William | Heston, Hailey | Bloyet, Louis-Marie | Pontelli, Marjorie Cornejo | Ilagan, Ma. Xenia G. | Jan Lebbink, Robert | Buchser, William | Wiertz, Emmanuel | Whelan, Sean | Ploegh, Hidde

Edité par CCSD ; National Academy of Sciences -

International audience. Significance Vaccines remain the best hope of curtailing SARS-CoV-2 transmission, morbidity, and mortality. Currently available vaccines require cold storage and sophisticated manufacturing capacity, complicating their distribution, especially in less developed countries. We report a protein-based SARS-CoV-2 vaccine that directly and specifically targets antigen-presenting cells. It consists of the SARS-CoV-2 Spike receptor-binding domain (Spike RBD ) fused to a nanobody that recognizes class II major histocompatibility complex antigens (VHH MHCII ). Our vaccine elicits robust humoral (high-titer binding and neutralizing antibodies) and cellular immunity against SARS-CoV-2 and its variants in both young and aged mice. VHH MHCII -Spike RBD is stable for at least 7 d at room temperature and can be lyophilized without loss of efficacy, desirable attributes for logistical reasons.

Consulter en ligne

Suggestions

Du même auteur

Defining the risk of SARS-CoV-2 variants on immune protection

Archive ouverte | Degrace, Marciela | CCSD

International audience. The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To add...

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Archive ouverte | Liu, Zhuoming | CCSD

International audience. Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19 vaccines and have received emergency use authorization as therapeutics. However, viral escape mutants c...

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Archive ouverte | Case, James Brett | CCSD

International audience. Antibody-based interventions against SARS-CoV-2 could limit morbidity, mortality, and possibly transmission. An anticipated correlate of such countermeasures is the level of neutralizing anti...

Chargement des enrichissements...